
    
      This study is an open label Phase II study aimed to recruit at least 20 patients with
      inoperable PDA and who are positive for CA19.9 pancreatic tumor marker. The presence of
      higher than normal levels of CA19.9 is the sole inclusion criteria. Patients will be given
      one tablet of V3-P daily and followed for three months.
    
  